Cipla Limited (CIPLA.BO)
| Previous close | 1,424.75 |
| Open | 1,429.05 |
| Bid | 1,423.55 x 0 |
| Ask | 1,424.95 x 0 |
| Day's range | 1,405.50 - 1,430.80 |
| 52-week range | 897.70 - 1,519.00 |
| Volume | |
| Avg. volume | 31,743 |
| Market cap | 1.149T |
| Beta (5Y monthly) | 0.37 |
| PE ratio (TTM) | 31.02 |
| EPS (TTM) | 45.88 |
| Earnings date | 10 May 2024 |
| Forward dividend & yield | 8.50 (0.60%) |
| Ex-dividend date | 21 Jul 2023 |
| 1y target est | N/A |
- Reuters
India pharma companies develop versions of Wegovy to get in on weight-loss windfall
Indian drugmakers aiming to grab a slice of the burgeoning weight-loss treatment sales pie, both at home and abroad, have begun developing their own versions of Novo Nordisk's wildly in demand Wegovy. With some analysts predicting a weight-loss market reaching $100 billion a year or more by the end of the decade, executives at Sun Pharma, Cipla, Dr Reddy's and Lupin -- some of the world's largest generic drugmakers -- all said they have started work on Wegovy versions. Novo Nordisk has been unable to produce enough Wegovy to meet demand in more than half a dozen countries where it has already launched, amid record global obesity rates and people looking for easier alternatives to diet and exercise.
PR NewswireCipla announces joint venture in the United States with Kemwell Biopharma and Manipal Education & Medical Group for global development and commercialisation of innovative Cell therapy products
Cipla (EU) Limited, UK a wholly owned subsidiary of Cipla Limited (BSE:500087; NSE: Cipla EQ], hereinafter referred to as Cipla has announced a strategic collaboration with Kemwell Biopharma Private Limited (through its subsidiary Kemwell Biopharma UK Limited) and Manipal Education & Medical Group (through its subsidiary MNI Ventures, Mauritius) to incorporate a joint venture in the United States. The primary goal of this joint venture is to develop and commercialise novel Cell therapy products
